Gynecologic Oncology

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the treatment landscape for patients with rare gynecologic cancers.

Lindsay West, MD, gynecologic oncologist, University of North Carolina (UNC) Department of Obstetrics and Gynecology, UNC School of Medicine, discusses pain management for patients with endometrial cancer.

Ann H. Klopp, MD, PhD, discusses optimizing the use of chemoradiation and the future of the treatment landscape in endometrial cancer.

David Mutch, MD, Ira C. and Judith Gall professor, vice chair of obstetrics and gynecology, chief, Division of Gynecologic Oncology, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses frontline treatment for patients with endometrial cancer.

The FDA has put a clinical hold on a phase I/II study of axalimogene filolisbac plus durvalumab (Imfinzi) for the treatment of patients with cervical cancer or head and neck cancer.

Lindsay West, MD, gynecologic oncologist, University of North Carolina (UNC) Department of Obstetrics and Gynecology, UNC School of Medicine, discusses the relationship between diet and endometrial cancer.

The FDA has granted a priority review to pembrolizumab (Keytruda) for the treatment of advanced cervical cancer with disease progression on or after chemotherapy.

Ann H. Klopp, MD, PhD, an associate professor of radiation oncology at The University of Texas MD Anderson Cancer Center, discusses the future of chemotherapy in combination with radiation for the treatment of patients with endometrial cancer.

David Mutch, MD, Ira C. and Judith Gall professor, vice chair of obstetrics and gynecology, chief, Division of Gynecologic Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses molecular biomarkers in endometrial cancer.

Ann H. Klopp, MD, PhD, an associate professor of radiation oncology at The University of Texas MD Anderson Cancer Center, discusses chemoradiation in endometrial cancer.

Adjuvant chemotherapy given during and after radiotherapy did not improve 5-year overall survival for patients with high-risk endometrial cancer in the phase III PORTEC-3 trial.

Lindsay West, MD, gynecologic oncologist, University of North Carolina (UNC) Department of Obstetrics and Gynecology, UNC School of Medicine, discusses the future of treatment for patients with gynecologic malignancies.

David G. Mutch, MD, discusses questions surrounding the role of radiation therapy for patients with high-risk endometrial cancer.

Standard cisplatin-based concomitant chemoradiation induced superior disease-free survival compared with neoadjuvant chemotherapy followed by radical surgery in women with locally advanced squamous cervical cancer.

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses novel combination strategies in gynecologic cancer.

David Mutch, MD, Ira C. and Judith Gall professor, vice chair of obstetrics and gynecology, chief, Division of Gynecologic Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses whether or not a patient with high-risk endometrial cancer should receive external beam radiation therapy.

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses pelvic exenteration surgery for patients with gynecologic cancer.

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the rationale behind novel combination strategies for patients with gynecologic cancer.

Many endometrioid cancers express high RNA levels for multiple immune checkpoints, and this may allow physicians to treat these patients with combination immune therapies.

Lindsay West, MD, gynecologic oncologist, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, discusses the challenges with quality of life for patients with gynecologic cancer.

Ingfrid Haldorsen, MD, University of Bergen, Haukeland University Hospital, on overcoming challenges with imaging in endometrial cancer.

An analysis of black women of Caribbean descent with type I or type II endometrial cancer showed that this population expressed significant differences in genetic variations compared with a nationwide population of patients with endometrial cancer.

Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses the future of treatments for patients with endometrial cancer.

Sharad Ghamande, MD, discusses the findings from GOG/NRG-0265, as well as the impact of vaccines for patients with cervical cancer.

Robert Coleman, MD, professor in the department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of ramucirumab (Cyramza) in patients with gynecologic cancer.

Women with a body mass ≥30 kg/m2 had a greater 5-year risk for cervical cancer than lighter women, possibly due to underdiagnosis of cervical precancer.

Ingfrid Haldorsen, MD, University of Bergen, Haukeland University Hospital, discusses the contributions of imaging in endometrial cancer.

Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses challenges with a trial (NCT00193791) conducted by Tata Memorial Hospital seeking to solidify the impact of concomitant chemoradiation with FIGO stage IIIb squamous cervical cancer.

Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses the management of endometrial cancer.

Martee L. Hensley, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses DNA mismatch repair deficiency (dMMR) and microsatellite-instability high (MSI-H) testing for patients with endometrial cancer.